Feb 16, 2022
In recent years, the overall survival from metastatic renal cell carcinoma (RCC) has improved, mainly in part due to immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI). TKI and ICI had distinct and...
Read MoreFeb 16, 2022
Lenvatinib (lenva) + pembrolizumab (pembro) demonstrated encouraging antitumor activity and controllable safety characteristics in treatment-naive (n=23) or earlier cured metastatic RCC (n=105, initially medicated with immune...
Read MoreFeb 15, 2022
Thursday, Feb 17: Exhibits Open 10:00 AM – 9:45 PM EST Novel Treatment Implementation: Prostate-Specific Membrane Antigen Targeting and Beyond Primary Track: Prostate Cancer 10:45 AM – 12:30 PM EST Optimizing Management of...
Read MoreFeb 15, 2022
Program at a Glance • Highly interactive sessions with multidisciplinary perspectives on new, innovative findings in the study, diagnosis, and treatment of GU malignancies. • Presentation of the latest novel science and...
Read MoreAug 25, 2021
Download ESC Congress 2021 Program (PDF)
Read MoreAug 25, 2021
Anticipation is rising for the European Society’s Annual Congress, an event like no other, providing access to ground-breaking science, essential clinical updates and the chance to interact with a renowned international...
Read MoreApr 16, 2021
Due to the COVID-19 pandemic, the 2021 American Academy of Neurology Annual Meeting, the world’s premier neurology meeting, will be held in a fully virtual format from April 17-22. It will include: Over 90 expert-led CME...
Read MoreApr 16, 2021
The study team compared disability accrual in primary and secondary progressive multiple sclerosis (PPMS, SPMS) in the international MSBase cohort, using multivariable survival models, and applying objective diagnostic criteria...
Read MoreApr 16, 2021
Management of patients with multiple sclerosis (MS) in the era of disease modifying therapies (DMT) relies heavily on magnetic resonance imaging (MRI). As physicians, decisions are influenced by the reporting prowess of...
Read More
